Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis By Sheena Cruz / 06/01/2026
Ublituximab significantly improves patient-reported outcomes: results from the phase 4 observational study ENABLE By Sheena Cruz / 05/26/2026
Evaluation of Ublituximab Infusion Tolerability: Analysis of Data Following the ULTIMATE Phase 3 Studies By Sheena Cruz / 05/26/2026
Evaluating the Presence and Concentration of BRIUMVI® (ublituximab-xiiy) in Breastmilk (PROVIDE): An Interim Report By Sheena Cruz / 05/26/2026
Real-World Transition to Ublituximab From Prior Anti-CD20 Treatment in the Phase 4 ENABLE Study By Sheena Cruz / 05/26/2026
Safety and Tolerability of a Modified Ublituximab Dosing Regimen: Updates from the ENHANCE Study By Sheena Cruz / 04/21/2026
Real-world Clinical Experience from ENABLE, the First Phase 4 Observational Study for Patients with Relapsing Multiple Sclerosis Initiating Ublituximab By Sheena Cruz / 04/21/2026
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis By Sheena Cruz / 03/09/2026
Five Years of Ublituximab in Multiple Sclerosis ULTIMATE I and II Open-Label Extension Study By Sheena Cruz / 02/17/2026
Study Design of a Phase 3, Randomized, Double-Blind Study of Ublituximab Versus Fingolimod in Children and Adolescents with Relapsing Multiple Sclerosis: ULTIMATE KIDS II By Sheena Cruz / 02/06/2026
